SBIR/STTR Research Award

A Nanopatterned Interdigitated Electrode Array Device for Anti migratory Cancer Drug Screening

Award identifier 14e0fecdece4c544bff7f98b0b5c14bc205c6afa532b631a03cce1b234182330Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$225,000

Program and phase

SBIR · Phase I

Award year

2017

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
CURI BIO, INC.
Proposal award date
2017-09-21
Contract end date
2018-06-20
UEI
D6VABZ7RVM84
Solicitation number
PA16-302
Topic code
102

Research abstract

PROJECT SUMMARY As the cancer drug industry suffers from the lowest success rate in developing cancer cure drugs cell migration assessment assays that evaluate the transition of cells from a benign to a metastatic phenotype have gained more attention Given the fact that metastatic cancer cells are substantially harder to eradicate than those that are benign migratory propensity is now understood to be a key metric in both assessing cell migration behavior and screening anti migratory compounds However conventional cell migration assays suffer from high cost of equipment labor intensive procedures and non biomimetic culture environment In addition high throughput real time quantification of collective cell migration requires live cell microscopic monitoring that requires expensive microscope systems and fluorescent cell labeling for automatic tracking Also most conventional cell migration assays are performed on flat culture surfaces which lack topographical or mechanical cues necessary to provoke a metastatic phenotype and induce fast directed collective cell migration observed during in vivo metastasis The proposed cell migration assay platform incorporating anisotropic nanopatterned polymer substrates provides a more robust alternative to chemotactic systems Enhanced biomimicry in this culture environment will enhance response sensitivity of the migrating cancer tissues in presence of test compounds yielding a more predictive assay In this proposed platform we propose to integrate unique ion permeable nanotopographic polymer substrates with a label free impedance based interdigitated electrode array IEA biosensor for detecting real time quantification of collective cell migration in a high throughput manner We hypothesize that changes in IEA impedance magnitude can be reproducibly correlated to the migration distance enabling real time calculation of migratory velocity of the collective cell cultures We further predict that such a relationship will permit the evaluation of dynamic nanotopographically guided tissue responses to anti migratory agents Finally we anticipate that aided by the proposed platformandapos s biomimetic nanotopography this system will significantly outperform prior art in its predictive capacity in evaluating cell migration kinetics To test these hypotheses single and multi well unpatterned and nanopatterned IEA sensors will be fabricated and integrated with a simple custom made impedance analyzer Reproducible correlations will be established between collective cellular migration distance and sensor impedance Once this correlation is established the IEA sensor will be used to test a series of pharmaceutical compounds through cellular migration assays Lastly nanopatterned culture data obtained through this project will be compared to scientific literature data to further evaluate the predictive utility of the proposed nanoIEA platform Successful validation of this nanoIEA system will clear the way for the commercialization of a product that stands to advance the efficacy of preclinical cancer drug screening thereby significantly leading to streamlined drug development PROJECT NARRATIVE We will develop a nanopatterned interdigitated electrode array nanoIEA device for anti migratory cancer drug screening We anticipate that the combination of the enhanced biomimicry resulting from in vivo like migration environment of this platform with a high throughput label free real time impedance sensing analyzer will provide more accurate efficient and predictive cell migration data than currently available commercial assays This nanoIEA based cell migration assay has great potential to become a more effective means for preclinical anti migratory cancer drug development

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

16 SBIR/STTR records share this UEI (2016–2024). Reported award amounts total $11,985,726. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.